These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 26063886)

  • 1. The Perfect Pathology Report After Neoadjuvant Therapy.
    Marchiò C; Maletta F; Annaratone L; Sapino A
    J Natl Cancer Inst Monogr; 2015 May; 2015(51):47-50. PubMed ID: 26063886
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Breast specimen handling and reporting in the post-neoadjuvant setting: challenges and advances.
    Mrkonjic M; Berman HK; Done SJ; Youngson B; Mulligan AM
    J Clin Pathol; 2019 Feb; 72(2):120-132. PubMed ID: 30670564
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Standardizing of Pathology in Patients Receiving Neoadjuvant Chemotherapy.
    Bossuyt V; Symmans WF
    Ann Surg Oncol; 2016 Oct; 23(10):3153-61. PubMed ID: 27380637
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The ever-evolving role of pathologists in the management of breast cancer with neoadjuvant treatment: recommendations based on the Spanish clinical experience.
    Burgués O; López-García MÁ; Pérez-Míes B; Santiago P; Vieites B; García JF; Peg V
    Clin Transl Oncol; 2018 Mar; 20(3):382-391. PubMed ID: 28795336
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mammographically directed breast biopsies: a College of American Pathologists Q-Probes study of clinical physician expectations and of specimen handling and reporting characteristics in 434 institutions.
    Nakhleh RE; Jones B; Zarbo RJ
    Arch Pathol Lab Med; 1997 Jan; 121(1):11-8. PubMed ID: 9111087
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Lack of Standardization in the Processing and Reporting of Post-Neoadjuvant Breast Cancer Specimens.
    Han R; Regpala S; Slodkowska E; Nofech-Mozes S; Hanna W; Parra-Herran C; Lu FI
    Arch Pathol Lab Med; 2020 Oct; 144(10):1262-1270. PubMed ID: 32142368
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Variability in gross and microscopic pathology reporting in excisional biopsies of breast cancer tissue.
    Apple SK
    Breast J; 2006; 12(2):145-9. PubMed ID: 16509839
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Processing and Reporting of Breast Specimens in the Neoadjuvant Setting.
    Bossuyt V
    Surg Pathol Clin; 2018 Mar; 11(1):213-230. PubMed ID: 29413658
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [GEFPICS' guidelines for management of breast cancer tissue samples in the neoadjuvant setting].
    Maran-Gonzalez A; Franchet C; Duprez-Paumier R; Antoine M; Barlier C; Becette V; Berghian A; Blanc-Fournier C; Brabencova E; Charafe-Jauffret E; Chenard MP; Dauplat MM; Delrée P; Fleury C; Garbar C; Ghnassia JP; Haudebourg J; MacGrogan G; Mathieu MC; Michenet P; Penault-Llorca F; Poulet B; Robin Y; Roger P; Russ E; Treilleux I; Valent A; Verriele V; Vincent-Salomon A; Arnould L; Lacroix-Triki M;
    Ann Pathol; 2019 Dec; 39(6):383-398. PubMed ID: 31257035
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Standardization of pathologic evaluation and reporting of postneoadjuvant specimens in clinical trials of breast cancer: recommendations from an international working group.
    Provenzano E; Bossuyt V; Viale G; Cameron D; Badve S; Denkert C; MacGrogan G; Penault-Llorca F; Boughey J; Curigliano G; Dixon JM; Esserman L; Fastner G; Kuehn T; Peintinger F; von Minckwitz G; White J; Yang W; Symmans WF;
    Mod Pathol; 2015 Sep; 28(9):1185-201. PubMed ID: 26205180
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinically relevant breast cancer reporting: using process measures to improve anatomic pathology reporting.
    Hammond EH; Flinner RL
    Arch Pathol Lab Med; 1997 Nov; 121(11):1171-5. PubMed ID: 9372744
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pathological assessment of resection specimens after neoadjuvant therapy for metastatic melanoma.
    Tetzlaff MT; Messina JL; Stein JE; Xu X; Amaria RN; Blank CU; van de Wiel BA; Ferguson PM; Rawson RV; Ross MI; Spillane AJ; Gershenwald JE; Saw RPM; van Akkooi ACJ; van Houdt WJ; Mitchell TC; Menzies AM; Long GV; Wargo JA; Davies MA; Prieto VG; Taube JM; Scolyer RA
    Ann Oncol; 2018 Aug; 29(8):1861-1868. PubMed ID: 29945191
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Neoadjuvant treatment of breast cancer: implications for the pathologist].
    Le Guellec S; Perallon R; Alunni JP; Charitansky H; Leaha C; Gonzalez AM; Chateau MC; Simony-Lafontaine J; Jacot W; Gutowski M; Penault-Llorca F; Dalenc F; Lacroix-Triki M
    Ann Pathol; 2011 Dec; 31(6):442-54. PubMed ID: 22172117
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Histological assessment of therapeutic response in breast cancer.
    Horii R; Akiyama F
    Breast Cancer; 2016 Jul; 23(4):540-5. PubMed ID: 24173652
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The importance of histological assessment after neoadjuvant therapy and the need for standardisation.
    Naidoo K; Pinder SE
    Clin Radiol; 2018 Aug; 73(8):693-699. PubMed ID: 29439778
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Gene expression profiles of breast cancer obtained from core cut biopsies before neoadjuvant docetaxel, adriamycin, and cyclophoshamide chemotherapy correlate with routine prognostic markers and could be used to identify predictive signatures.
    Rody A; Karn T; Gätje R; Kourtis K; Minckwitz G; Loibl S; Munnes M; Ruckhäberle E; Holtrich U; Kaufmann M; Ahr A
    Zentralbl Gynakol; 2006 Apr; 128(2):76-81. PubMed ID: 16673249
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Characterization and clinical impact of residual disease after neoadjuvant chemotherapy.
    Viale G
    Breast; 2013 Aug; 22 Suppl 2():S88-91. PubMed ID: 24074800
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Standards, Options and Recommendations (SOR) for drafting of anatomic and surgical pathology reports or cytopathology reports in oncology].
    Arnould L; Fiche M; Blanc-Vincent MP; Le Doussal V; Zafrani B; Gory-Delabaere G; Briffod M; Vielh P; Voigt JJ
    Bull Cancer; 2000 Feb; 87(2):159-71. PubMed ID: 10705287
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Role and evaluation of pathologic response in early breast cancer specimens after neoadjuvant therapy: consensus statement.
    Guerini-Rocco E; Botti G; Foschini MP; Marchiò C; Mastropasqua MG; Perrone G; Roz E; Santinelli A; Sassi I; Galimberti V; Gianni L; Viale G
    Tumori; 2022 Jun; 108(3):196-203. PubMed ID: 34918596
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pathological controversies in breast cancer: classification of ductal carcinoma in situ, sentinel lymph nodes and low volume metastatic disease and reporting of neoadjuvant chemotherapy specimens.
    Provenzano E; Brown JP; Pinder SE
    Clin Oncol (R Coll Radiol); 2013 Feb; 25(2):80-92. PubMed ID: 23199579
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.